Clinical Trials Browser

Phase 2 × Lymphoma × tafasitamab × Clear all

NCT07030699 2026-03-06

ECLAT

Phase 2 Recruiting

Lymphoma

NCT07126236 2025-08-17

REPIFIR

Phase 2 Recruiting

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse